Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes [published erratum appears in J Exp Med 1988 Oct 1;168(4):1517] by unknown
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Lipooligosaccharides (LOS)' of Neisseria are heterogeneous mixtures of glycolipids
ofM r 3,200-7,000 as estimated by migration in SDS-PAGE (1, 2) . LOS components
have epitopes that have been definedby variousmAbs (1-3). Apicella et al. (3) found
thatmAb 3F11 recognized acommon epitopeon gonococcalLOS that wasalso found
on some meningococcalLOS. A second mAb, 06B4, was shown to have a specificity
very similar to that of 3F11 (2). Both mAbs bind to an epitope on a 4.8-kD LOS
(1, 2) that is made by all but three of over 90 gonococcal strains thatwe have exam-
ined (one of the negative strains is the pyocin-resistant mutant,JW31R [2, 4, 5]).
The epitope defined by 06B4 is also expressed on theLOS ofmany strains of Neis-
seria meningitides, whereas the 3F11-defined epitope is expressedonly occasionally on
meningococcalLOS (6) . Apicella et al. (3) used monosaccharide and disaccharide
ELISA inhibition data to suggest that the 3F11-defined epitope was composed of
Ga1NAc-Gall-4GIc, a structure similar to the terminal oligosaccharide found on
some meningococcalLOS. The chemical specificity of06B4 has not been defined.
Jennings and colleagues (7-9) have reported the structures of the carbohydrate
portions ofpartially degraded LOS of three meningococcal strains of differentLOS
serotypes(an L2 strain, L3,7,9 strain andanL5 strain) . The same terminal tetrasac-
charideoccupied thenonreducingendoftheLOSmoleculesof each of these strains.
This terminal structure (Ga101-4GIcNAc01-3Gal01-4Glc) is identical to the ter-
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minal tetrasaccharide (lacto-N-neotetraose, LNnT) of paragloboside (nLc4Cer), a
glycosphingolipid precursor ofthe major human blood group antigens (10), and ter-
minates in the disaccharide N-acetyllactosamine (LacNAc). Although complete chem-
ical structures have not been reported for the oligosaccharides of any gonococcal
LOS, several laboratories have reported that the LOS of various strains were com-
posed ofdifferent ratios ofthe same monosaccharides (Gal, Glc, G1cNAc, Hep, dOclA)
as meningococcal LOSS (11-16).
The chemical identity of the terminal LNnT of meningococcal LOS and of
nLc4Cer suggested that the two glycolipids might also share epitopes and that
human and neisserial cellsmight express the same antigenic structures. Since mAbs
06134 and 3F11 bind to the LOS of some meningococcal and most gonococcal strains,
and the latter is specific for a LacNAc-containing structure that could be represented
on nLc4Cer, we decided to use them as probes to look for the presence of struc-
tures on human cell surfaces that are immunochemically similar to thosewithin neis-
serial LOS.
Since the development of immunochemical procedures for detecting antibody
binding to glycosphingolipids (17, 18), these compounds have proven useful in deter-
mining the oligosaccharide binding specificities ofmAbs. TLC immunostaining and
solid-phase binding assays used in conjunction with a variety ofpurified glycosphin-
golipids of known structure have made it possible to determine the fine differences
in the oligosaccharide binding specificities of mAbs. This report describes the pres-
ence of an immunochemically similar structure on the gonococcal and human eryth-
rocyte cell surfaces and describes the use of glycosphingolipids of known structure
to determine the fine specificity of mAbs 3Fll and 06B4 that identify this conserved
epitope.
Materials and Methods
Bacterial Strains.
￿
Neisseriagonorrhoeae strains 56 and 220 were kindly providedby Dr. Herman
Schneider (Walter Reed Army Institute of Research, Washington, DC) and have been exten-
sively characterized (1, 2, 13). Strain 56 is sensitive to lysisby normal human sera (ser'); 220
is serum resistant (serr). The Neisseria meningitides prototype strains for LOS serotypes have
also been described previously (19-22). The meningococcal strains used in this study are of
the following serotype classifications (19, 23): 126E (C:3 :P1.2:L1,8), 35E (C:20:P1.1:L2,5), 1381
(C:2a:P1.2:L3), 891 (C :11:L4), 118V (C:?:L2,4), 6155 (B:2a:P1 .2:L7,3). Culture procedures
for each Neisseria were described [1, 19].
Lipooligosaccharides.
￿
LOS were extracted from saline-washed or acetone-dried organisms
by the hot phenol-water method (13, 24). Stock solutions of LOS used in solid-phase RIA
(SPRIA) were prepared as described previously (2). Briefly, LOS was dissolved in 50 mM
Na0H, heated for 1 h at 37 °C, then carefully neutralized with 50 mM HCl and stored at 4°C.
Monoclonal Antibodies.
￿
mAbs were kindly provided by Drs. Michael A. Apicella (06B4,
3fll) andJulie Westerink (1F10), State University ofNew York, Buffalo; and William W Young,
Jr. (1132), University of Virginia Medical School, Charlottesville, VA. The preparation and
characteristics of mAbs 06B4 (2), 3F11 (1-4), and 1B2 (25) have been reported. mAb 1F10
was prepared as described (3); it is specific for meningococcal group A polysaccharide. mAbs
06B4 and 3F11 were prepared from cells of mice immunized with a gonococcal strain and
mAb 1F10 was prepared from cells ofmice immunized with a group A meningococcal strain.
mAb 1B2 was prepared from immunocytes of mice that had been inoculated with the
N-acetyllactosamine glycosphingolipid, lacto-N-norhexaosylceramide, nLc6Cer, (Galpl-
4G1cNAc(31-3Galfil-4G1cNAcp1-3Galp1-4Glc-Ceramide), which had been hydrophobi-
callycomplexed to Salmonella minnesota (25). mAb 1B2 agglutinates human adult, but not fetal,1v1ANDRELL ET AL.
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erythrocytes when incubated with them at 4°C (25); this hemagglutinating activity can be
inhibited by N-acetyllactosamine glycosphingolipids including some that represent various
I blood group antigens.
All four mAbs are of the IgM class. The concentrations of mAbs 06B4, 3F11, and 1B2
were 3.65, 0.47, and 0.16 mg/ml, respectively, as determined by a modification (2) of a quan-
titative SPRIA (26).
Human Erythrocytes and Hemagglutination Assay.
￿
Adulthumanbloodspecimens were obtained
from the hematology laboratory of the San Francisco VA Medical Center and from colleagues
in our laboratory. Infant blood samples were obtained from unused specimens from the hema-
tology laboratory of the Moffitt-Long Hospital/UCSF Medical Center, San Francisco, CA.
We determined the blood type of each human erythrocyte specimen with mouse monoclonal
anti-A and anti-B, and rabbit polyclonal anti-D grouping reagents (Ortho Diagnostics, Rar-
itan, NJ).
A small aliquot of cells was washed four times with PBS, pH 7.2, and then suspended to
2% cells in PBS. The 2% cell suspensionwas then added to an equal volume of twofold dilu-
tions of mAbs in PBS, incubated for 2 h at the designated temperature, and then examined
for agglutination. We scored agglutination as follows: complete agglutination, pellet with crin-
kled edges = 3+ ; complete agglutination, absence of settled cells = 2+ ; partial agglutina-
tion, presence of partially clumped cells = 1+; no agglutination, settled cells with no visible
clumping after remixing pellet = 0. The data are presented as the concentration of mAb
at the highest dilution producing 1+ agglutination or as the reciprocal ofthat dilution ofmAb.
Enzymatic Treatment ofErythrocytes.
￿
To identify specificity for cryptic antigens, mAbs were
tested in parallel with cells that had been treated with either trypsin or neuraminidase. A
150-pl aliquot ofwhole blood was washed four times with PBS and the cells resuspended in
150 pl of PBS. After dividing the cell suspension into three equal aliquots, an equal volume
of either PBS (pH 6.0), trypsin (2.5 mg/ml in PBS, pH 7.2; type IIIS, Sigma Chemical Co.,
St. Louis, MO), or neuraminidase (25 mg/ml in PBS, pH 6.0; type V, Sigma Chemical Co.)
was added. The mixtures were incubated for 1 h at 37°C and then washed three times with
PBS to remove enzyme and degradation products. The cells were further treated as described
above.
Affinity Purification ofmAb 3F11 with Enzyme-treatedHuman Erythrocytes (RBC-3F11).
￿
We used
differential binding at 4°C and 37 °C of mAb 3F11 to adult erythrocytes to purify mAb 3F11
from ascites. A 300-pl aliquot of mAb 3F11 was incubated with 300 pl of packed trypsin-
treated adult human erythrocytes for 1 h at 4°C . The erythrocytes were pelleted and then
washed extensively with PBS at 4°C to remove unbound ascites. A 500-p1 aliquot of PBS
was added to the pelleted cells and the mixture was incubated in a 37°C water bath for 30
min to elute the bound antibodies. We pelleted the cells and used the SPRIA and SIDS
PAGE/immunoblot analysis to test whetherthe supernatant contained eluted antibody (RBC-
3F11) to LOS from various meningococcal and gonococcal strains.
SDS-PAGE and Immunoblot Analysis.
￿
LOS were separated by SDSPAGE by the method
of Laemmli (27), as slightly modified (2). LOS were separated by electrophoresis through
duplicate slab gels. The LOS in one slab was stained with silver (28) and the LOS in the
other slab was electroblotted to nitrocellulose paper. The immunoblot analysis has been de-
scribed (29). The paper was cut, incubated in a "filler" buffer consisting of 1 % casein in 10
mM Tris-hydrochloride/150mM NaCl/5mM MgC12/30 mM NaN3 (pH 7.4), and was in-
cubated for 1 h with the appropriate mAb diluted to N5 pg/ml in filler buffer. The antibody-
treated nitrocellulose papers were washed and then incubatedwith an alkaline phosphatase-con-
jugated goat anti-mouse IgM (Sigma Chemical Co., St. Louis, MO) diluted 1:200 in filler
buffer. The papers were washed three times with PBS and once with 50 mM Tris/HCI, pH
8.0. A solution consisting of0.2% Fast Red TR salt (Sigma Chemical Co.) and 0.1% naphthol
AS MX phosphoric acid (Sigma Chemical Co.) dissolved in 50 mM Tris-HCI, pH 8.0 was
added to the paper. The color reaction was stopped when no further color development was
noted (usually 5-7 min). Photographs were made ofthe dried papers. All antibody stepsand
washes were done at room temperature on a rotating shaker. We identified the components
that bound mAbs by reference to component profiles from previous mAb studies with these
mAbs and LOS from gonococcal strains (1, 2).110
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SPRIA with mAb 3F11, 06B4, and IB2 .
￿
The binding ofmAbs to neisserial LOSS was as-
sessed by a previously described SPRIA (20, 26) . Briefly, plastic microtiter wells were sensi-
tized with 25 gg/ml concentrations ofmeningococcal or gonococcal LOS, followed by the ad-
dition of fourfold dilutions of each of the mAbs . LOS were diluted in Dulbeccds PBS, pH
7.4 (containing 20MM MgC12) ; mAb and secondary antibodies were diluted in filler buffer
(see above). After incubatingthe plates overnight, we removed antigen and washed the wells .
Bound mAb was quantified with use of "'I-goat anti-mouse IgM (Kirkegaard and Perry,
Gaithersburg, MD) . The wells were washed and cut, after they had incubated with secondary
antibody for 6 h . Bound radioactivity was measured with a gamma counter.
DifferentLOS bound different amounts ofeachmAb at saturation, as judged by the binding
of secondary antibody . To compare the relative expression of each epitope among different
LOS, the LOS that bound the most mAb at saturation was assigned a value of 100% and
the amount ofmAb that bound to each of the other LOS was expressed as a percentage of
the highest binding . Comparisons among different mAbs that bound a particular LOS were
limited to negative or positive because ofdifferences amongmAb affinities and the goat anti-
bodies against the different mouse Igs . Comparisons among different LOSS that bound a
particular mAb could be made quantitatively.
Glycosphingolipids.
￿
Total neutral glycosphingolipids fromhuman erythrocytes were purified
by standard procedures (30) . Preparation ofother glycosphingolipids has been described pre-
viously (30, 31) .
TLCImmunostaining .
￿
The immunostaining procedure for the TLC plates has been de-
scribed in detail (32). The TLC conditions used in each experiment are presented in the
figure legends .
Binding Assays with Glycosphingolipids.
￿
Solid-phase binding assays and the ELISA proce-
dure with purified glycosphingolipids have recently been described (33) .
Results
Structural Similarities betweenLOS andBlood GroupAntigens.
￿
Jennings and colleagues
(7-9) have reported the structure of three meningococcal strains of different LOS
serotype (Table 1). LNnT (GalOl-4G1cNAca1-3Ga1(31-4Glc) is the nonreducing
terminus of the oligosaccharides of each of these strains (7-9). Since LNnT is also
the terminal tetrasaccharide of the major blood group antigen precursor, nLc4Cer
(Table I), this structural similarity led us to test forimmunochemical similarity be-
tween human cells and LOS.
Binding ofmAbs to Meningococcal LOS.
￿
Because of the LNnT structure present in
meningococcal LOS (7-9), we tested mAbs for binding to multiple serologically di-
verse meningococcal LOS. Table II compares the SPRIA binding activity with LOS
of eight prototype meningococcal LOS serotype strains by mAbs (3Fll and 06B4)
that identify conserved and similar epitopeson gonococcal LOS. In contrast to studies
with gonococcal LOS, the 3F11 and 06B4 epitopes were expressed on a lower per-
centage ofmeningococcal LOS and were not always coexpressed on the meningococcal
LOS. mAb 3F11 bound to the LOS of 3/8 strains ; mAb 06B4 bound 5/8 LOS. The
mAb-defined epitopes were coexpressed only on strains 6155 and 120M . Strains 35E,
6275, 891, and M981 expressed one or the other, but not both, epitopes . We then
tested human adult erythrocytes with mAbs 3Fll and 06B4 .
Binding ofmAbs 3F11 and 06B4 to Adult Human Erythrocytes.
￿
Table III compares
the binding ofmAbs 3F11 and 06B4 with adult human erythrocytes, as judged by
agglutination . mAb 3F11 (23.5 pg/ml) agglutinated all 47 specimens at 4°C, regard-
less oftheir blood type . mAb06B4 agglutinated 38 (80%) of these same erythrocyte
specimens ; higher concentrations (>175 gg/ml) of mAb 06B4 failed to agglutinateTABLE I
Structures of Three Different Meningococcal LOS and Erythrocyte Glycosphingolipids
I, i, and Paragloboside
Sample
￿
Structure
￿
Reference
` The oligosaccharide portion of the LOS molecule is shown.
Cer, ceramide.
For I antigen, the branched form of nLcsCer is most active with various human cold agglutinins (10).
t
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TABLE II
SPRIA Binding` of mAbs to LOSfrom Meningococcal Prototype
LOS Serotype Strains
To compare the relative expression ofeach epitope among different LOS, we
assigned a value of 100% to the LOS that bound the most mAb at saturation,
and expressed the amount of the same concentration of mAb that bound to
each other LOS as a percentage of the first LOS. 5% was arbitrarily selected
as the positive cutoff value. As each LOS is a mixture of different LOS com-
ponents, relative binding reflects the relative proportion of LOS bearing the
mAb-recognized epitope among all the LOS made by the population of that
strain from which the LOS was extracted (64, 65).
Numbers in parentheses indicate minor serotypes (<50% inhibition oftyping
serum) (20).
Strain L type$ mAb 06134 mAb 3F11
126E L1,8 <1 <1
35E L2 15 <1
6275 L3 20 <1
891 L4 100 <1
M981 L5 1 6
6155 L7,3 96 100
M978 L8,3,(4,7) <1 2
120M L9,7,(4,6) 81 100
Strain 1 LOS Galpl-.4G1cNAcpl-3Gals1-4GIcpl-4Hepa1-5KDO 7
3
at
1
GIcNAcal-2Hep
Strain 2 LOS Galpl-+4GIcNAcpl-3Galp1-4GIcp1-4Hepa1-5KDO 8, 9
3
at
1
GlcNAcal-2Hep3-1aGlc
Strain 3 LOS Galpl-4GIcNAcp1-3Galp1-4Glcpl-4Hepa1-5KDO 8, 9
3
at
1
GIcNAcal-2Hep3-laGlc
paragloboside (nLc4Cert) Galpl-4G1cNAcpl-3Galp1-4GIcp1-1Cer 62
i antigen (nLc6Cer) Galpl-.4G1cNAcp1-3Galp1-4GIcNAp1-3Galpl-4Glcp1-1Cer 63
I antigen (nLc8Cer)S Galpl-4G1cNAcp1-6y
Galpl-4G1cNAp1-3Galp1-4GIcp1-ICer 63
Galp1-4G1cNAcp1-+31GONOCOCCOL AND MENINGOCOCCAL LIPOOLIGOSACCARIDE
TABLE III
Agglutination of Adult Human Erythrocytes by mAbs Specific for
Neisserial LOS
` Number (%) of samples of each ABO type that agglutinated with the mAb.
MAbs were tested at a concentration of 23.5 pg/ml and 182 pg/ml for 3F11
and 06B4, respectively. Neither BALB/c nor New Zealand White rabbit erythro-
cytes were agglutinated by either mAb at these concentrations.
the remainingnine specimens. Agglutination with 3F11 wasalways greater than with
06B4, even though 06B4 was used at nearly a sevenfold higher antibody concentra-
tion (182 pg/ml) compared with 3F11 (23.5 gg/ml). On the basisof the limited number
of samples analyzed there was no obvious correlation between agglutinability by
mAb 06B4 and ABO type of erythrocytes. Neither mAb agglutinated erythrocytes
from BALB/c mice nor New Zealand White rabbits (data not shown).
Effect of Temperature on Agglutination ofAdult Human Eythrocytes.
￿
Agglutination by
mAb 3F11 was optimal at incubation temperatures of 4°C. A 2-3 log decrease in
agglutination titer occurred at temperatures of 22°C and 37°C (Table IV). Cells
that agglutinated with a 3 + reaction at 4°C were easily disrupted and resuspended
when the cells reequilibrated to room temperature. mAb 06114 also agglutinated
erythrocytes better at 4°C than 37 ° C.
BindingofRBC-3F11 andIB2to Meningococcal and GonococcalLOS.
￿
Thecontrasting
expression of the mAb-defined epitopes on erythrocytes at 4°C and 37°C, proved
useful as a method for purifying the erythrocyte (RBC) binding antibody (RBC-
3F11) from ascites. Erythrocyte-purified mAb 3F11 (RBC-3F11) bound to the LOS
TABLE IV
Effect of Temperature on Agglutination ofAdult Human Erythrocytes
by mAb 3F11
Reciprocal ofthe dilution of mAb 3F11 that resulted in 1 + agglutination; RBC
samples 2 and 3 were not agglutinated at 37'C by undiluted mAb. See Materials
and Methods for criteria for scoring agglutination reactions.
RBC N
Agglutinated"
3F11
by:
06B4
A+ 15 15(100) 14(93)
B+ 5 5 (100) 4(80)
AB+ 1 1 (100) 1 (100)
0+ 21 21 (100) 17 (81)
A - 3 3 (100) 1 (33)
B - 1 1 (100) 0(0)
0- 1 1 (100) 1 (100)
Total 47 47 (100) 38(81)
RBC
sample 40C
Agglutination titer'
220C 370C
1 >1,000 10 10
2 >1,000 10 1
3 >1,000 10 1
4 >1,000 10 10MANDRELL ET AL .
TABLE V
Comparison of Binding to Neisserial LOS by
mAbs 1B2, 3F11, RBC-3F11, and 06B4
mAbs were tested in aSPRIA ; binding activity was designated as a percentage
of themaximum binding value for that mAb, as described in Materials and
Methods .
1 mAb 1B2 is specific to glycolipids having a nonreducing terminal N-acetyl-
lactosamine (Galsl-4G1cNAcO1-+R) (25) .
of gonococcal strains 220 and 56 and meningococcal strain 6155, but not to menin-
gococcal strains 891 and 126E (Table V) . The similar binding activity ofRBC-3F11
and unpurified 3F11 suggests that theLOS and erythrocyte epitopes are defined by
themAb andnotby acontaminating polyclonal antibody. This wasfurther confirmed
by the binding to neisserial LOS by mAb 1B2, which was produced in amouse im-
munized witha glycosphingolipid foundonhuman erythrocytes and specific for ter-
minal N-acetyllactosamine (Galpl-4G1cNAc) . The LOS-binding pattern of mAb
1B2 was the same as that of mAb 3F11 (Table V) . mAb 06B4 differed from those
of 3F11, 1B2, and RBC-3F11 in that it bound 891 LOS .
Immunoblot Analysis of Neisserial LOS with mAbs .
￿
Each of the mAbs that bound
a particular LOS in SPRIA also bound at least one component of that LOS after
separation of the components by SD&PAGE . Fig. 1 shows the silver-stained profile
of each of the five LOS tested forbindingof 1B2 in the SPRIA (Table V) and their
FIGURE 1 .
￿
SDS-PAGE/immunoblot analysis of mAbs 3Fll, 06B4, 1B2, and RBC-3F11 with
gonococcal (220 and 56) and meningococcal (126E, 891, 6155) LOS. Lane 1, 56 LOSS lane 2,
220 LOS ; lane 3, 6155 LOSS lane 4,891LOS ; lane 5,126E LOS. (A) Silver-stained gel ; (B)immu-
noblot with 3F11; (C)immunoblot with RBC-3Fll; (D) immunoblot with 02 ; (E) immunoblot
with 06B4 . The binding of mAbs 3Fi1, 1B2, and RBC-3Fli are very weak to 56 LOS, but can
be seen on the original blot . Electroblotted LOS incubatedwith each ofthe reagents, except mAb,
showed no color development .
LOS of strain'
mAb 126E 891 6155 220 56
1B21 <1 <1 43 100 58
3F11 <1 <1 27 100 70
RBC-3F11 <1 <1 33 100 71
06114 <1 35 50 100 31114
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TABLE VI
Agglutination of Human Adult and Infant Erythrocytes by mAb 3F11
VA, adult specimens obtained from Veterans Administration Hematology
Laboratory.
t Concentration (gg/ml) of mAbs at highest dilution producing 1 + agglutina-
tion. See Materials and Methods for criteria for scoringagglutination reaction.
immunoblot profilewith each ofthemAbs. RBC-3F11, 1B2, 3F11, and06B4allbound
to a component of 220, 6155, and 891 LOS of -4,800 Mr and to a component of
56 LOS of-5,000 Mr. None ofthe mAbs bound to 126E LOS which lacks the 4,800
Mrcomponent. In addition, each ofthe three mAbs, although negative for 891 LOS
in the SPRIA binding assay, were positive for the LOS after separation ofthe com-
ponentsbySDS-PAGE (Fig. 1, lane 4). A "negative-control" paperwithelectroblotted
LOS treated with all reagents except mAb, was completely negative, even after >10
min of color development.
Binding ofmAb 3F11 to Infant Human Erythrocytes.
￿
Becauseofthe similar specificity
ofmAbs 3F11 and 1B2 and the reported activity of 1B2 (Table V and Fig. 1) with
Erythrocyte
source Age`
ABO
type
mAb
concentrationt
Infant 8 1 d O - >23.5
Infant 13 2 d O + >23.5
Infant 10 2 d O + >23.5
Infant 1 4 d A + >23.5
Infant ? 4 d A + 5.9
Infant s 5 d O + >23.5
Infant 12 8 d A + >23.5
Infant 4 9 d O + >23.5
Infant 9 18 d A + 2.9
Infant 3 28 d O - >23.5
Infant 11 30 d O + >23.5
Infant 2 85 d A + 1 .5
Infant 6 200 d B - >23.5
Child 1 1 yr O - 0.4
Child 2 4 yr AB + 0.4
Adult 2 VA B + <0.4
Adult 4 VA O + <0.4
Adult 1 17 yr O + 0.4
Adult 3 VA A - 0.7
Adult 6 VA A + 1 .5
Adult 10 VA A + 1 .5
Adult 13 VA O + 1 .5
Adult 5 VA B + 2.9
Adult 7 VA B + 2.9
Adult 8 VA B + 2.9
Adult 12 VA O + 2.9
Adult 16 VA A + 2.9
Adult 9 VA B + 5.9
Adult 11 VA O + 5.9
Adult 14 VA A + 5.9
Adult 15 VA O + 5.9MANDRELL ET AL .
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TABLE VII
Effect on Agglutination by mAb 3F11 of Neuraminid4se and
Trypsin Treatment of Erythrocytes
Concentration (pg/ml) ofmAb 31711 at highest dilution producing 1 + agglu-
tination (see Materials and Methods) .
human adult and cord erythrocytes, we tested for the ability ofmAb 31711 to ag-
glutinate infant cells. Only 3 of 13 erythrocyte specimens from infants <7 mo old
were agglutinated by the mAb, even at concentrations of 23.5 gg/ml (Table VI) . This
was in contrast to adult cells, all of which were agglutinated by <6 Rg/ml of mAb
31711 . Erythrocytes from 1- and 4-yr-old children had a similar reactivity as adult
cells in that they were agglutinated by only 0.4 leg/ml of 31711 .
EffectofEnzymatic Treatment on Binding ofmAb 31711 to Human Erythrocytes.
￿
Thefailure
of31711 to agglutinate most ofthe infant erythrocyte specimenscould reflect blocking
of the epitope by other sugars such as sialic acid and/or by large glycoproteins in
the erythrocyte membrane. A second possibility is the delayed expression of theap-
propriate glycosyltransferases involved in the developmental changes in the glyco-
proteins and glycolipids in the erythrocyte membranes(10) . We addressed thesetwo
possibilities, by investigating the effect oftreatmentof erythrocytes with neuramini-
dase or trypsin on theiragglutinability withmAb31711 (Table VII).A representative
group ofthreeinfantand four adulterythrocyte sampleswere each treated separately
with the two enzymes . None of the infants' cells were agglutinated by 23.5 gg/ml
ofmAb 31711 ; the adults' cells were all agglutinated by <2 Ng/ml. Treatment ofboth
adult andinfant cellswith either enzyme markedly increased their sensitivity to ag-
glutination. After treatment all seven samples were agglutinated by <0.2 ug/ml of
31711 . Enzymatic treatmentof adult cells increased theexpression ofthe 31711-defined
epitope at all assay temperatures; however, epitope expression at room temperature
or 37°C remained 1 and 2 logs less, respectively, than that at 4°C . In a control ex-
periment, high concentrations (40-50 gg/ml) of a mouseIgMmAb specific forgroup
A polysaccharide, mAb 11710, did not agglutinate either untreated or treated infant
or adult cells . Thesedata suggestthat the 31711-definedepitope is present, butblocked
on infant erythrocytes .mAb06114 also agglutinated infant erythrocytes treatedwith
neuraminidase, but not untreated erythrocytes . In a preliminary experiment with
a small number of specimens of infant erythrocytes, neuraminidase-treated infant
erythrocytes were agglutinated better by 06114 than by 31711. mAb 06114 aggluti-
Concentration ofmAb resulting in
agglutination of erythrocytes
Source of ABO treated with :'
erythrocytes type Untreated Neuraminidase Trypsin
Infant 1 A + >23.5 <0.2 <0 .2
Infant 3 O - >23.5 <0.2 <0 .2
Infant 5 O + >23.5 <0.2 <0 .2
Adult 2 B + <0 .2 <0 .2 <0.2
Adult 4 O + 0 .4 <0 .2 <0.2
Adult 6 A + 1 .5 <0 .2 <0.2
Adult 13 O + 0 .7 <0 .2 <0.2116
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FIGURE 2.
￿
Thin-layer chromatogram
of glycosphingolipids immunostained
with mAbs 3FI1 and06B4 . (A)Human
erythrocyte neutral glycosphingolipids
stained with orcinol reagent (lane 1),
andimmunostained withMl (lane 2) ;
06B4 (lane 3). (B) nLc4Cer purified
from human myeloid cells immuno-
stained with 3FI1 (lane 1) and 06B4
(lane 2). (C) Rabbit erythrocyte
branched-chain nLcsCer (see Fig . 3
for structure) immunostained with
3F11 (lane 1); 06B4 (lane 2) . TLC
plates were developed in a standard
solvent tank (A) or in a short bed con-
tinuous development tank (B and C)
(32) in chloroform/methanol/water,
60/35.8, vol/vol .
nated-treated infant erythrocytes at a concentration ofmAb two- to fourfold lower
than the concentration of 3F11 necessary for the same activity (data not shown) .
DeterminationofCarbohydrate Sequence Specificity ofmAbs. To determine the carbohy-
drate sequence specificity recognized by the mAbs, the antibodies were tested with
purified glycosphingolipids ofknown carbohydrate structure . Fig . 2 shows aTLC
ofhuman erythrocyte neutral glycosphingolipids and otherpurified glycosphingolipids
immunostained with 3F11 and 06B4 . PanelA shows that both 3F11 and 06B4 are
able to bind aseries of neutral glycosphingolipids isolated from human erythrocytes,
and give qualitativelysimilar patterns . Lane1ofFig . 2A shows a chemically stained
chromatogram of the erythrocyte neutral glycosphingolipids . As shown by the im-
munostaining patterns in lanes 2 (3F11) and3 (06B4), the glycosphingolipids that
theseantibodies bind areminorcomponents, accounting foronlyasmallpercentage
of the orcinol-stained compounds. Neither antibody bound to the major red cell
glycosphingolipid Gb4Cer (see Fig . 3 for structure) . All of the immunostained
glycosphingolipids are more polar than Gb4Cer, and thus contain four ormore sac-
charides . PanelBdemonstrates that both antibodies are able to bind to the purified
glycosphingolipid nLc4Cer (Fig . 3) and appear to have qualitatively similar affinity
for this compound . Panel C shows the bindingof these two antibodies to abranched
biantennary glycosphingolipid (Fig. 3, rabbit erythrocyte branched chain nLc8Cer),
whichwas prepared by treatment ofthe rabbit erythrocyte glycosphingolipid C-deca
(Fig . 3) with a-galactosidase. Fig. 2 clearly shows that 3F11 (panel C, lane 1) binds
more strongly to the biantennarybranched-chain glycosphingolipid than does 06B4
(panel C, lane 2) .
Comparison of Binding Affinities of 3F11, 06B4 and IB2.
￿
To quantify the relative
affinities of3F11 and06B4 forlinear versus branched-chain lactosamine compounds,
a solid-phase binding assay was done using the avidin-biotin-alkaline phosphatase
ELISA assay method (33) . Fig . 4A shows a plot of the binding of 3F11 and 06B4
to different quantities of nLc4Cer . Both antibodies bound with high affinity to this
compound, showing significant binding at 250 ng and reaching a plateau at 1,000
ng . The antibody 1B2 showed a similar binding curve to those obtained with 3F11
and 06B4.Gatpl-4GkNAcp1-K
cajPj-)4G1cNAcft1-+3Ga1Pw4Gkcer
I
Ga1P1-MGIcNAcP1-43
(Rabbit aydtrocytebaaachad daisftLa,Ca)
B Galph3GkNAcpl-+3Gatst-+4Gkca
(ILc ca)
Gala1-+3Ga1pl-*4G1cNAcp1-*a
Galpl~ecicrMpt~3Gals1-r4Mccr
(aLC,Cer)
Gaipi-i4GicNAc¢i-+3Gal0l-*4GIcNAcpt~3Galpl -+4GkCu
(aL4cer)
Ga1p1-4GicNAepl~3Galpl-+4CIcNAcpl-i3GalAt-+4GkNAcpt~3Gat9 1-AGkCer
(nt.c ca)
GaINAcpl-+3Galal->4Gatpl-}4Gkca
(Gb,C")
Gaial->3Gaipi-t4GkNAcpi-+3Gaip1-t4CkCa
av'Gatale,C-)
NcuAca2-+3Galot-4GieNAcpt-t3Galpl-t4GteCer
(1V'NeuAcnL4,Cer)
Gatpl-44(Pacat-a3)GkNAcpl-+3Galpl-i4GicNAcpl~3Galpt-t4Glcca
(111'116ML4Cer)
Galat-+3Galp1-44GicNAcpt~3
(Rabbit erythrocyte Cdeca)
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FIGURE 3. Glycosphingolipids reac-
tive (A)andunreactive (B)with inAbs
3F11, 06B4, and IB2.
A comparison ofthe bindingaffinity ofthe same threeantibodies forthe bianten-
nary glycosphingolipid, nLcaCer, is shown in Fig. 4 B. In contrast to the results ob-
tained with the straight-chain glycosphingolipid, nLc4Cer, 3Fll and 06B4 gave
markedlydifferent bindingcurves with the branched-chain compound. The affinity
of3F11 forthebranchedcompound wasthreetofivetimes greaterthanthatof06B4.
Interestingly, 1B2 paralleled the binding of 3F11, showing an equally high affinity
for nLcaCer.
BindingofrnAbsto OtherGlycosphingolipids.
￿
Tofurtherevaluatethebindingspecificity
of3F11 and 06114, TLC immunostaining assays were done with anumberofpurifiedE e
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BindingofmousemAbs 3F11 and
06B4 to linear andbranched-chain N-acetyl-
lactosamine glycosphingolipids. The solid-
phase binding assay (ELISA) was used to
quantify thebinding of 3F11, 06B4, and 1B2
to purified glycosphingolipids. The label on
the x-axis refers to the micrograms of mAb
addedto microtiter well.(A)Antibody binding
to nLc4Cer. (B) Antibody binding to rabbit
erythrocyte branched-chain nLcsCer. 3F11
(p); 06B4 (A) 1B2 (+).
glycosphingolipids. Fig. 3 summarizes these results, and shows that both antibodies
bind to glycosphingolipids of the neolacto family (nLc4Cer, nLc6Cer, linear and
branched nLc8Cer), but only if the nonreducingterminal disaccharide N-acetyl lac-
tosamine is unsubstituted. Addition of a terminal sialic acid (IV'NeuAcnLc4Cer)
or galactose residue (IV3GaInLc4Cer), or a branching fucose at the penultimate
glucosamine (III3FucnLc4Cer) blocked binding. Glycosphingolipids of other fami-
lies globo (Gb4Cer) and lacto (LC4Cer) were not recognized. Compounds with less
than four sugar residues including G1cNAc(31-3GalO1-4G1cCer, were not recog-
nized by either antibody (data not shown).
Discussion
These data show that the glycolipids in the membranes of gonococci and human
red blood cells share a highly,conserved and exposed epitope. In addition, the epi-
tope defined by mAb 3F11 is also expressed on some meningococcal LOS (Table
II) (34). The epitope is expressed more effectively at 4°C incubation temperatures
and on adult erythrocytes better than on infant erythrocytes (Tables III, IV, and
VI). Acomparison of 3F11 hemagglutinating activity with erythrocytes from human
adults and infants showed a stronger expression of the 3F11 antigen on adult cells
(Table VI), but increased expression on infant cells after enzymatic treatment of
the cells. The increased expression of the 3F11 epitope on infant cells after enzy-MANDRELL ET AL .
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matic treatment with trypsin and neuraminidase (Table VII) is probably due to en-
zymatic stripping ofthe glycoprotein molecules blocking epitopes recognized by 3F11
and to hydrolysis of sialic acids capping terminal lactosamine structures, respectively .
Agglutination ofuntreated adult erythrocytes at 4°C likely is a result of a conforma-
tion shift at low temperatures of the position of large membrane glycoproteins that
are blocking epitopes .
The expression ofthe 3F11 epitope on LOS was not affected by temperature. Im-
munoblot assays performed at room temperature and SPRIA performed at either
room temperature or 37 °C resulted in equivalent or slightly increased expression
of the LOS 3F11 epitope (data not shown). These results are consistent with those
ofhuman cold agglutinin-binding activity, at 4°C and 37°C, with erthrocytes or
antigens removed from erythrocytes (35) .
The fact that mAb 3F11 : (a) had a differential binding activity with human adult
and infant erythrocytes (Table VI), (b) bound to infant erythrocytes after enzymatic
treatment of the cells (Table VII) and (c) agglutinated cells better at 4°C compared
with higher temperatures (Table IV), suggests that mAb 3F11 may have activity similar
to human cold agglutinins (36-38) . The existence ofhuman cold agglutinins has
been known formany years (39-41) . They are paraprotein molecules, usually ofthe
IgM subclass, and usually specific for one or more of the molecules that compose
the Ii blood group antigen system (10) . The human myeloma paraprotein, Ma, has
ahuman adult/cord cell activity very similar to 3F11 (42), while a second myeloma
paraprotein, McC, has an inverse binding activity to Ma and 3F11 in that at 4°C
it agglutinates infant cells better than adult cells (38) . The McC cold agglutininwas
shown to be specific fornLc4Cer (38) . Two otherhuman cold agglutinins, Woj and
Sti (43), are similar in specificity to mouse mAb 1132 . These antibodies all are specific
for N-acetyllactosamine carbohydrate structures .
mAb 1132 was made in a mouse immunized with nLc6Cer and was shown to be
specific for glycosphingolipids with N-acetyllactosamine structures and to bind to
adulthuman erythocytes, but not to umbilical cord erythrocytes (25) . We haveshown
in this study that 1132and 3F11 also have a similar reactivity pattern with gonococcal
and meningococcal LOS, and this pattern differedfrom that of 06134 in SPRIA (Table
V), but not in SDSPAGE/immunoblot analysis (Fig . 1).
Although mAbs 3F11 and 06134 appeared quite similar with a variety ofLOS (2)
(Table V), other LOS from group B and C meningococcal strains bound 06134, but
not 3F11 (Table II ; Dr . Janice J . Kim, personal communication) . This may be a
reflection of differences in the presence of the LOS components bearing the mAb-
recognized epitope. For example, the expression of the 3F11/1132- and 06134-defined
epitopes on 891 was markedly different . mAbs 3F11 and 1132 did not bind to 891
in any of severalSPRIAs (Tables II and V), but bound weakly to 891 after separation
ofthe LOS bySDSPAGE (Fig. 1) .A difference in epitope expression in these binding
assays suggests a conformational difference in the 3F11/1132 epitope in LOS on a
plastic surface in the SPRIA and LOS after separation by SDSPAGE and transfer
to nitrocellulose . Although the basis for the subtle expression differences of the epi-
topes defined by these antibodies is not yet clear, binding assays using 3F11, 06134,
and 1132 with purified human erythrocyte and neutrophil glycosphingolipids that
have linearand branching N-acetyllactosamine structures provided information rele-
vant to this expression difference .
Young et al. (25) demonstrated that 1132 has a higher affinity for nLc4Cer than120
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nLc6Cer in some assays (complement-mediated liposome release assay, solid-phase
binding assay), whereas inothers (complement fixation andhemagglutination inhi-
bition assays), the affinity was the same for both compounds. Thus, all three anti-
bodies have a similar affinity for nLc4Cer.
The results with purified glycosphingolipid-binding assays complement and ex-
tend theresults ofthebindingassays withpurifiedLOS(Tables II andV) and hemag-
glutination assay (Table III), which demonstrated that 3F11 and 06B4 had similar,
but not identical, binding specificities. The finding that 06B4 preferentially binds
tolinear type 2 glycosphingolipids isingoodagreement withtheearlierobservation
that human fetal erythrocytes largely contain glycosphingolipids and glycoproteins
with linear type 2 N-acetyllactosamine chains (10, 44-46) and withour preliminary
resultsshowing that 06B4 agglutinates neuraminidase-treatedhuman infant erythro-
cytes at least as well as does 3F11. The fact that 3F11 has a high affinity for both
linear and branched type2 glycosphingolipids also agrees well withthe factthatadult
erythrocytes have both linear and branched chain components (10, 44-46).
Thebinding properties of3F11 and 06B4 aresimilar to thoseoftwo otherantilac-
tosamine mousemAbs (M39.6 and M18.3) characterized by Gooi et al. (43). How-
ever, there appear to be important subtle differences in the fine specificities ofthese
antibodies. For example, M18.3 does not bind to nLc4Cer and M39.6 is only reac-
tivewith relatively large amounts (1 wg) ofthis glycosphingolipid (43), whereas both
3F11 and 06B4 bind to much lower amounts of nLc4Cer. Finally, 3F11 and 06B4
appear to have similar binding properties to those of another mouse mAb, My28
(47). My28 was generated by immunizing mice with human myeloid cells. These
cells are known to be rich in linear lactosamine glycosphingolipids. My28 binds to
nLc4Cer and longer-chain, linear lactosamine glycosphingolipids; However, its rel-
ative affinity for branched-chain structures has not been reported.
It is important to stress that only furtherLOS structural datawill reveal whether
analogous linear and branching LOS epitopes exist and whetherthey are different
quantitatively inmeningococcalandgonococcal LOS. Theantibodiesdescribed, how-
ever, will be useful tools in further studies on glycoconjugates and neisserial LOS.
Many ofthe carbohydrate structures recognized bythe antibodies describedabove
represent intermediate molecules in the development of blood group antigens.
nLc4Cer is the precursor structure for i antigen (46) (Table I). Human fetal erythro-
cytes predominately express i antigen. The structure ofi on infant erythrocytes is
not completely defined, but itisthoughttobeaform ofthelinear N-acetyllactosamine
glycosphingolipid, nLc6Cer (Galo1--"4G1cNAco1-3Galo1-4GlcNAc(31-3Gal(31-
4Glc-Cer) (10, 48, 49). By 4-6 mo ofage the concurrent expression or derepression
of a glycosyltransferase enzyme (branching enzyme) results in the attachment of
N-acetyllactosamine to the subterminal galactose residue ofi and the synthesis of
I (Table I) onhuman erythrocytes (50). The addition ofother substituents (fucose,
sialic acid, lactosamine) tothetwo branches ofthenascent Imolecule resultsinmul-
tiple forms of I that are recognized by various cold agglutinins (10, 42), including
some agglutinins that have been mentioned above. Ii are precursors ofthe ABH
blood group antigens (10).
Ourstudieshave demonstrated an immunochemical similarity betweenneisserial-
LOS and antigens present onhuman erythrocytes. The involvement ofimmunochem-MANDRELL ET AL.
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ically similar structuresin gonococcal pathogenicity would be dependent on the pres-
ence of the antigens on the relevant host tissues. Although we have only demon-
strated similar antigens on red cells, the presence of Ii antigens and/or nLc4Cer have
been detected on human lymphocytes, monocytes, polymorphonuclear leukocytes
(51), other granulocytes (31, 47, 52, 53), and in various human fluids, including milk,
urine, and saliva (54). Also, in recent studies mAb 1B2 has been used to detect traces
of nLc4Cer- and nLc6Cer-containing glycolipids in human semen (55).
How could the presence ofa blood group antigen precursor structure on the gono-
coccus potentially provide an advantage to the bacteria in human tissue with similar
structures? First, the host could not mount an effective immune response to bac-
terial antigens similar to self . It has been shown, for instance, that normal human
sera do not have functionally efficient antibodies to nLc4Cer, nor to other
glycosphingolipids of similar structure (56). If immunochemically similar antigens
were predominate on the gonococcal cell surface, these may block or alter the binding
of potentially protective human antibodies and complement.
Second, LOS with a terminal N-acetyllactosamine structure potentially could act
as sites of attachment or adhesion to host cells. Human cells have been shown to
possess surface lectins that bind to various polylactosaminylglycans that terminate
in GalD1-4G1cNAc and/or that contain internal Galsl-4Glc (57, 58). Lectins with
such a specificity on human epithelial cells may play a role in attachmentofbacteria
possessing lactosamine structures.
If similar carbohydrate structuresare present on the host and parasite cell surface
then these cells may also possess similar glycosyltransferase enzymes. Human host
cells having surface glycosyltransferases that play a role in the completion of blood
group antigens on lactosamine (Galo1-4GIcNAc) precursors might bind to an im-
munochemically similar substrate on the gonococcal cell surface (LOS oligosaccha-
ride) and remain bound in the absence of the optimal conditions required for enzy-
matic reactivity (optimal pH, sugar-nucleotide concentrations, metals, or other
cofactors). This concept has been proposed by Roseman (59) as a potential mecha-
nism of the involvement of multiglycosyltransferase systems in intercellular adhe-
sion. Although most glycosyltransferases are found exclusively inside the cell in the
Golgi apparatus, some evidence of cell surface galactosyltransferase on ciliated cells
of human fallopian tube epithelium (60) and on the mouse sperm surface (61) has
been reported.
Third, when optimal conditions do exist for enzymatic activity then host cell
glycosyltransferasesreleased from damaged cells(sperm, menstrual debris) may alter
the bacterial cell surface, resulting in neoantigens to which the host is tolerant. Con-
versely, the release of bacterial glycosyltransferases on host tissue substrates could
result in new tissue antigens to which the host is intolerant, thus leading to host
cell damage.
The presence on the gonococcus of a structure immunochemically similar to the
precursor of human blood group antigens (ABH) is intriguing. Further studies of
the human immune response to LOS, LOS/lectin binding, LOS/glycosyltransferase
binding, mAb inhibitionofattachment, and production of neoantigens on LOS will
be required to determine what role they play in the pathogenic mechanisms ofNeis-
seria gonorrkoeae and Neisseria meningiddis.122
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Summary
We have used mouse mAbs, 3Fll and 06B4, that are specific for highly conserved
epitopes ofNeirseria gonorrhoeae lipooligosaccharides (LOS)to identify immunochem-
ically similar structures on human erythrocytes. mAb 3F11 agglutinated erythro-
cytes from all randomly selected adult humans, while mAb 06B4 agglutinated only
80 % ofthe same specimens. The antibodieshad an activity with erythrocytes similar
to human cold agglutinins in that the agglutination occurred at 4°C and decreased
with increasing incubation temperature. Human infant erythrocytes were aggluti-
nated less well, but enzymatic treatment of either infant or adult cells resulted in
an increase in expression of the 3F11- and 06B4-defined epitopes. Both antibodies
bound to a series of neutral glycosphingolipids from human erythrocytes and neu-
trophils that have a type 2 (Galsl-4GlcNAc) or N-acetyllactosamine structure. Nei-
ther antibody bound to glycosphingolipids from human meconium, which have a
type 1 (Gals1-3GlcNAc) structure. The antibodieswere unable to bind to N-acetyl-
lactosamine glycosphingolipids with a nonreducing terminal sialic acid or a Galal-
3Gal disaccharide. Antibody binding also was blocked by the presence of fucose linked
to the penultimate glucosamine residue of N-acetyllactosamine glycosphingolipids.
Although both antibodies bound to linear and branched-chain N-acetyllactosamine
glycosphingolipids, 3Fll had a higher affinity for branched structures than did 06B4.
The activity of 3F11 with human adult and infant treated and untreated erythro-
cytes with N-acetyllactosamine glycosphingolipids, and with LOS was very similar,
if not identical, in specificity to 1B2, an mAb prepared from mice inoculated with
a linear N-acetyllactosamine glycosphingolipid.
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